「in vitroinvivoin vitroinvivo」の検索結果
161件：66～70件目を表示
-
-700 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediat...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240726.pdf -
rmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., L...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
rmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., L...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716.pdf -
Production | About Senju | SENJU Pharmaceutical
Trusted pharmaceutical products are created using the latest and best equipment in the environment with rich humanity. As ophthalmic solutions are required to meet the same quality standards as inject...
http://www.senju.co.jp/english/about/production.html -
产品开发方针 | 研究与开发 | 千寿制药株式会社
人以上未得到必要的治疗。并且报告中还提到白内障、屈光不正（近视、老花眼等）、老年性黄斑变性、青光眼、糖尿病性视网膜病变等是导致全球性视力受损或失明的主要原因。 为创造针对眼部疾病的高价值（First in Class、Best in Class、提升患者便利性等）的产品，今后，我们也将全力推进研究开发活动。我们从“对导致视力受损或失明的眼部疾病的贡献”、“满足未满足的医疗需求*”、“商业化的可能性...
http://www.senju.co.jp/chinese/rd/policy/